These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3678067)

  • 1. Adverse drug events: identification and attribution.
    Rogers AS
    Drug Intell Clin Pharm; 1987 Nov; 21(11):915-20. PubMed ID: 3678067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicaid drug-event data: an emerging tool for evaluation of drug risk.
    Jones JK; Van de Carr SW; Rosa F; Morse L; LeRoy A
    Acta Med Scand Suppl; 1984; 683():127-34. PubMed ID: 6377830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods.
    Rossi AC; Knapp DE; Anello C; O'Neill RT; Graham CF; Mendelis PS; Stanley GR
    JAMA; 1983 Apr 22-29; 249(16):2226-28. PubMed ID: 6834622
    [No Abstract]   [Full Text] [Related]  

  • 5. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing surveillance methodologies.
    Edlavitch SA
    Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better reporting of adverse drug reactions.
    Abrutyn E
    Ann Intern Med; 1985 Feb; 102(2):264-5. PubMed ID: 3966766
    [No Abstract]   [Full Text] [Related]  

  • 8. Medication monitoring in the workplace: toward improving our system of epidemiologic intelligence.
    Tilson HH
    J Occup Med; 1990 Apr; 32(4):313-9. PubMed ID: 2335797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing surveillance of adverse reactions to drugs.
    Rawlins MD
    Br Med J (Clin Res Ed); 1984 Mar; 288(6421):879-80. PubMed ID: 6423125
    [No Abstract]   [Full Text] [Related]  

  • 10. Postmarketing surveillance of adverse reactions to drugs.
    Inman WHW
    Br Med J (Clin Res Ed); 1984 Apr; 288(6424):1155-6. PubMed ID: 6424767
    [No Abstract]   [Full Text] [Related]  

  • 11. Techniques of postmarketing surveillance. An overview.
    Carson JL; Strom BL
    Med Toxicol; 1986; 1(4):237-46. PubMed ID: 3537618
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse drug reaction reporting.
    Bosco LA
    Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
    [No Abstract]   [Full Text] [Related]  

  • 13. Prescription-event monitoring and yellow cards.
    Inman WH
    Lancet; 1984 Jun; 1(8389):1301. PubMed ID: 6145011
    [No Abstract]   [Full Text] [Related]  

  • 14. Post-marketing surveillance of new drugs.
    Buckley EG
    J R Coll Gen Pract; 1987 Aug; 37(301):337-8. PubMed ID: 3448222
    [No Abstract]   [Full Text] [Related]  

  • 15. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 16. The epidemiological evaluation of drugs.
    Shapiro S
    Acta Med Scand Suppl; 1984; 683():23-7. PubMed ID: 6588735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reactions to new drugs.
    Venning GR
    Br Med J (Clin Res Ed); 1983 Mar; 286(6370):1052-3. PubMed ID: 6403183
    [No Abstract]   [Full Text] [Related]  

  • 18. Definition of events associated with drugs: regulatory perspectives.
    Jones JK
    J Rheumatol Suppl; 1988 Oct; 17():14-9. PubMed ID: 3204615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reaction monitoring: doing it the French way.
    Moore N; Biour M; Paux G; Loupi E; Begaud B; Boismare F; Royer RJ
    Lancet; 1985 Nov; 2(8463):1056-8. PubMed ID: 2865527
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse event detection in drug development: recommendations and obligations beyond phase 3.
    Berlin JA; Glasser SC; Ellenberg SS
    Am J Public Health; 2008 Aug; 98(8):1366-71. PubMed ID: 18556607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.